Abstract: Methods and devices to prevent and/or treat breathing disorders (e.g., upper airways disorders) in mammals related to impaired airflow are described. Methods and devices apply force to soft tissue that avoids obstruction of airflow in the mammel's airway. Breathing disorders that are avoided by the methods and/or devices include apnea.

Abstract: Methods of using clostridial toxins and other biological agents to thin skin and control fine wrinkles in humans are provided. In preferred embodiments the methods provide beneficial effects in humans.

Abstract: Methods of using clostridial toxins and other biological agents to thin skin and control fine wrinkles in humans are provided. In preferred embodiments the methods provide beneficial effects in humans.

Abstract: Embodiments of the invention include methods and devices to prevent or treat upper airway disorders in mammals related to impaired airflow. One aspect of this invention is a tongue retractor (LTR) that indirectly retracts tongue base by its implant site in the frenulum area. This simplifies the insertion, adjustment and maintenance of the device. Another aspect of this invention describes a highly localized and fully implantable LTR that is inserted into the base of tongue to stiffen lax surface mucosa or mechanically couple it to internal tongue structures. Another aspect of this invention is an LTR inserted in or around the pharyngoglossal fold. This site allows retraction and stiffening of tongue base tissue as well as the soft palate and lateral pharyngeal wall.

Abstract: Methods of using clostridial toxins and other biological agents to control holocrine gland dysfunction in humans is provided. In preferred embodiments the methods provide beneficial effects in humans.

Abstract: Compositions and methods of modulating cellular function and treatment of disease in mammals comprising locally administering a regulated SNARE inhibitor and a translocating agent to the mammal. Regulated SNARE inhibitors include clostridial neurotoxins, tetanus neurotoxin and their free light chain portions and IgA protease. Translocating agents include acids, encapsulating vectors, and transduction domains.

Abstract: A method is disclosed for blocking or reducing physiological reaction in a mammal to the interaction of IgE antibodies present in said mammal upon contact with the corresponding antigen, by the administration to said mammal of a therapeutically effective amount of a neurotoxin (CnT) derived from Clostridia sp.

Abstract: Methods of using clostridial toxins and other biological agents to control holocrine gland dysfunction in humans is provided. In preferred embodiments the methods provide beneficial effects in humans.

Abstract: Methods of using tetanus toxin to modulate or control neural functions or normeural cellular activities at selected sites in animals, particularly in mammals, and more particularly in humans, are provided. Pharmaceutical formulations to modulate neural functions or non-neural cellular activities of an animal at selected sites in animals, particularly in mammals, and more particularly in humans are also provided. Uses of tetanus toxin in preparation of medicaments for methods of treating clinical disorders or symptoms of animals, particularly mammals and more particularly humans are also provided.

Abstract: Airway obstruction in a patient with bilateral impairment of mobility of the vocal cords may be relieved by a method comprising implanting an electrode of a neural electrical stimulator comprising a pulse generator such that the electrode stimulates the posterior cricoarytenoid muscle, thereby resulting in abduction of the vocal cords and relief of airway obstruction. This method of relieving airway obstruction is based, at least in part, on the discovery that the implantation of an electrical pulse generator previously used in the stimulation of the spinal cord into a dog model of human BVCP was successful in chronically stimulating the PCA without the development of significant muscle abnormality.

Abstract: There is disclosed according to the present invention a method for the control of autonomic nerve function in a mammal comprising administering a therapeutically effective amount of botulinum toxin to the mammal. Preferred embodiments include administering the toxin to control the function of an autonomic nerve which contributes to at least one symptom of rhinorrhea, otitis media, excessive salivation, asthma, COPD, excessive stomach acid secretion, spastic colitis or excessive sweating.

Abstract: A method and devices for transcutaneous or transmucosal stimulation of the recurrent laryngeal nerve are provided. Recurrent laryngeal nerve stimulation is delivered by applying electric charge from an electrode in the form of a probe or an indwelling device to the intact neck skin at specific points along the tracheoesophageal groove or to mucosa within the esophagus, larynx, or trachea. In accordance with the present invention vocal cord excursion is related to frequency of the electrical stimulus.

Abstract: A method and devices for transcutaneous or transmucosal stimulation of the recurrent laryngeal nerve are provided. Recurrent laryngeal nerve stimulation is delivered by applying electric charge from an electrode in the form of a probe or an indwelling device to the intact neck skin at specific points along the tracheoesophageal groove or to mucosa within the esophagus, larynx, or trachea. In accordance with the present invention vocal cord excursion is related to frequency of the electrical stimulus.